Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Rama Nandipati

Pulmonary Disease Merced, CA Medical Doctor

NPI 1962583096 CMS profile 180381

450 E Yosemite Ave Ste A, Merced, CA 95340

Open in the dashboard

General payments

$4,621

247 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Rama Nandipati of Merced, CA is reported in the CMS Open Payments database as having received $4,621 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $967 49
2021 General $1,494 94
2020 General $1,170 60
2019 General $990 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rama Nandipati
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Rama Nandipati were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Rama Nandipati Pulmonary Disease median Middle half National median
2019 $990 $377 $109–$1,340 $163
2020 $1,170 $230 $56–$907 $114
2021 $1,494 $269 $68–$1,072 $132
2022 $967 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. GlaxoSmithKline, LLC. $1,040 57 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $876 48 payments
  3. AstraZeneca Pharmaceuticals LP $672 33 payments
  4. Teva Pharmaceuticals USA, Inc. $302 27 payments
  5. Genzyme Corporation $219 8 payments
  6. Philips Electronics North America Corporation $170 9 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $159 5 payments
  8. Grifols USA, LLC $152 16 payments
  9. Regeneron Healthcare Solutions, Inc. $149 10 payments
  10. Fisher & Paykel Healthcare Inc $125 7 payments
  11. Other $755 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,621 247 payments
Products named General payments · program years 2019–2022
  1. TRELEGY ELLIPTA $717 40 payments
  2. SPIRIVA RESPIMAT $339 23 payments
  3. ANORO ELLIPTA $258 14 payments
  4. AirDuo Digihaler $256 25 payments
  5. STIOLTO RESPIMAT $237 13 payments
  6. OFEV $230 8 payments
  7. BREZTRI $222 9 payments
  8. FASENRA Respiratory $213 9 payments
  9. FASENRA Respiratory $179 8 payments
  10. DUPIXENT $173 8 payments
  11. Other $2,471 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$4,405

Medicare's payments for the services billed

Medicare patients

81

Average age 74

Services billed

84

43 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 35%
Chronic kidney disease 30%
Atrial fibrillation 28%
Ischemic heart disease 26%
Heart failure 19%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record